Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Polyrizon Ltd. ( (PLRZ) ) has issued an update.
On April 27, 2026, Polyrizon Ltd., a Nasdaq-listed development-stage biotech specializing in intranasal hydrogels, reported that it filed a divisional European patent application for its Trap & Target (T&T) intranasal drug delivery platform. The move builds on a recently announced U.S. patent application covering both its Capture and Contain (C&C) nasal blocker and T&T drug delivery technologies, signaling a broad effort to secure intellectual property around its nasal platforms.
The T&T system aims to increase drug residence time in the nasal cavity, improve bioavailability, enable controlled release, prevent dripping, and use biodegradable polymers compatible with multiple drug classes. By targeting indications such as allergic rhinitis, epileptic seizures, and opioid overdose, the filing underscores Polyrizon’s bid to strengthen its position in advanced nasal drug delivery and respiratory health, potentially enhancing its attractiveness to partners and investors if the patents are ultimately granted.
More about Polyrizon Ltd.
Polyrizon Ltd. is a development-stage biotech company focused on innovative intranasal medical device hydrogels delivered as nasal sprays to create a thin barrier in the nasal cavity against viruses and allergens. Its core Capture and Contain (C&C) technology, based on naturally occurring building blocks, is designed as a “biological mask,” while its earlier-stage Trap and Target (T&T) platform targets intranasal delivery of active pharmaceutical ingredients for diverse therapeutic uses.
Average Trading Volume: 51,829
Technical Sentiment Signal: Hold
Current Market Cap: $27.74M
For an in-depth examination of PLRZ stock, go to TipRanks’ Overview page.